Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis

International Journal of Molecular Medicine

Volumn 41, Issue 4, 2018, Pages 1992-2002

  Wu, Xiongjian ^a   Zhi, Fachao ^a   Lun, Weijian ^a   Deng, Qiliang ^a   Zhang, Wendi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Baicalin; Hepatic fibrosis; Long chain fattyacid CoA ligase 4; Mir 3595

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BAICALIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DESMIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; LONG CHAIN FATTY ACID COENZYME A LIGASE 4; MICRORNA; MICRORNA 3595; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACSL4 PROTEIN, RAT; BECAPLERMIN; COENZYME A LIGASE; ENZYME INHIBITOR; FLAVONOID; PLANT EXTRACT; PLATELET DERIVED GROWTH FACTOR B; PROTECTIVE AGENT; SCUTELLARIA BAICALENSIS EXTRACT;

3' UNTRANSLATED REGION; APOPTOSIS; APOPTOSIS RATE; ARTICLE; CELL ACTIVATION; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HSC-T6 CELL LINE; MRNA EXPRESSION LEVEL; PERCENTAGE OF CELLS IN G0/G1 PHASE; PERCENTAGE OF CELLS IN S PHASE; PRIORITY JOURNAL; PROTEIN EXPRESSION LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; UPREGULATION; ANIMAL; CHEMISTRY; FIBROSIS; HEPATIC STELLATE CELL; LIVER; METABOLISM; PATHOLOGY; RAT; SCUTELLARIA BAICALENSIS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COENZYME A LIGASES; ENZYME INHIBITORS; FIBROSIS; FLAVONOIDS; HEPATIC STELLATE CELLS; LIVER; MICRORNAS; PLANT EXTRACTS; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-SIS; RATS; SCUTELLARIA BAICALENSIS; SIGNAL TRANSDUCTION;

EID: 85041561772     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2018.3427     Document Type: Article

References (60)

1. Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clinical Gastroenterol 25: 195-206, 2011.
2. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669, 2008.
3. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C and Pinzani M: Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 50: 1102-1111, 2009.
4. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
5. Popov Y and Schuppan D: Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatology 50: 1294-1306, 2009.
6. Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172, 2008.
7. Szabo G and Bala S: MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10: 542-552, 2013.
8. Wong L, Yamasaki G, Johnson RJ and Friedman SL: Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 94: 1563-1569, 1994.
9. Wu CI, Hoffman JA, Shy BR, Ford EM, Fuchs E, Nguyen H and Merrill BJ: Function of Wnt/β-catenin in counteracting Tcf3 repression through the Tcf3-β-catenin interaction. Development 139: 2118-2129, 2012.
10. Takase S, Takada A, Yasuhara M, Sato H and Matsuda Y: Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterol Jpn 23: 639-645, 1988.
11. Fu Y, Zheng S, Lin J, Ryerse J and Chen A: Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 73: 399-409, 2008.
12. Chen SR, Chen XP, Lu JJ, Wang Y and Wang YT: Potent natural products and herbal medicines for treating liver fibrosis. Chin Med 10: 7, 2015.
13. Peng XD, Dai LL, Huang CQ, He CM and Chen LJ: Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. World J Gastroenterol 15: 4720-4725, 2009.
14. de Oliveira MR, Nabavi SF, Habtemariam S, Erdogan Orhan I, Daglia M and Nabavi SM: The effects of baicalein and baicalin on mitochondrial function and dynamics: A review. Pharmacol Res 100: 296-308, 2015.
15. Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, Wang CC and Tsukamoto H: Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-Activated receptor gamma in hepatic stellate cells for their antifibrotic effect. Hepatology 55: 1271-1281, 2012.
16. Zhu QJ: Research advances on baicalin and baicalein as potential therapeutic agents for fibrotic disease. Zhongguo Zhong Yao Za Zhi 42: 1271-1276, 2017 (In Chinese).
17. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, et al: Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143: 765-776.e3, 2012.
18. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS and Gao B: Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 56: 1150-1159, 2012.
19. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
20. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-Transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
21. Teng KY and Ghoshal K: Role of noncoding RNAs as biomarker and therapeutic targets for liver fibrosis. Gene Expr 16: 155-162, 2015.
22. Lewin TM, Kim JH, Granger DA, Vance JE and Coleman RA: Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. J Biol Chem 276: 24674-24679, 2001.
23. Lewin TM, Van Horn CG, Krisans SK and Coleman RA: Rat liver acyl-CoA synthetase 4 is a peripheral-membrane protein located in two distinct subcellular organelles, peroxisomes, and mitochondrial-Associated membrane. Arch Biochem Biophys 404: 263-270, 2002.
24. Yan S, Yang XF, Liu HL, Fu N, Ouyang Y and Qing K: Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: An update. World J Gastroenterol 21: 3492-3498, 2015.
25. Liang YC, Wu CH, Chu JS, Wang CK, Hung LF, Wang YJ, Ho YS, Chang JG and Lin SY: Involvement of fatty acid-CoA ligase 4 in hepatocellular carcinoma growth: Roles of cyclic AMP and p38 mitogen-Activated protein kinase. World J Gastroenterol 11: 2557-2563, 2005.
26. Lin X, Kong LN, Huang C, Ma TT, Meng XM, He Y, Wang QQ and Li J: Hesperetin derivative-7 inhibits PDGF-BB-induced hepatic stellate cell activation and proliferation by targeting Wnt/β-catenin pathway. Int Immunopharmacol 25: 311-320, 2015.
27. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
28. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.
29. Golej DL, Askari B, Kramer F, Barnhart S, Vivekanandan-Giri A, Pennathur S and Bornfeldt KE: Long-chain acyl-CoA synthetase 4 modulates prostaglandin E(2) release from human arterial smooth muscle cells. J Lipid Res 52: 782-793, 2011.
30. Cooke M, Orlando U, Maloberti P, Podestá EJ and Cornejo Maciel F: Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4. J Lipid Res 52: 1936-1948, 2011.
31. Schuppan D: Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Semin Liver Dis 10: 1-10, 1990.
32. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ and Sobin LH: The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 31: 395-414, 1978.
33. Mormone E, George J and Nieto N: Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193: 225-231, 2011.
34. Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW and Tsukamoto H: Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 279: 4820-4828, 2004.
35. Gressner AM: Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: A key event in hepatic fibrogenesis. Kidney Int (Suppl 54): S39-S45, 1996.
36. Woodhoo A, Iruarrizaga-Lejarreta M, Beraza N, García-Rodríguez JL, Embade N, Fernández-Ramos D, Martínez-López N, Gutiérrez-De Juan V, Arteta B, Caballeria J, et al: Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology 56: 1870-1882, 2012.
37. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stöger U, Arrese M, Pizarro M, Solís N, et al: Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175: 2392-2405, 2009.
38. Sharvit E, Abramovitch S, Reif S and Bruck R: Amplified inhibition of stellate cell activation pathways by PPAR-gamma, RAR and RXR agonists. PloS One 8: e76541, 2013.
39. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, et al: A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153: 601-613, 2013.
40. Li T, Eheim AL, Klein S, Uschner FE, Smith AC, Brandon-Warner E, Ghosh S, Bonkovsky HL, Trebicka J and Schrum LW: Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: Potential therapeutic target for liver injury. Hepatology 59: 2383-2396, 2014.
41. Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H and Tontonoz P: Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 140: 1052-1062, 2011.
42. Zhu NL, Asahina K, Wang J, Ueno A, Lazaro R, Miyaoka Y, Miyajima A and Tsukamoto H: Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem 287: 10355-10367, 2012.
43. Delgado I, Carrasco M, Cano E, Carmona R, García-Carbonero R, Marín-Gómez LM, Soria B, Martín F, Cano DA, Muñoz-Chápuli R and Rojas A: GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice. Hepatology 59: 2358-2370, 2014.
44. Baylor NW, Fu T, Yan YD and Ruscetti FW: Inhibition of human T cell leukemia virus by the plant flavonoid baicalin (7-glucuronic acid, 5, 6-dihydroxyflavone). J Infect Dis 165: 433-437, 1992.
45. Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW and Wang JM: Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun 276: 534-538, 2000.
46. Zeng Y, Song C, Ding X, Ji X, Yi L and Zhu K: Baicalin reduces the severity of experimental autoimmune encephalomyelitis. Braz J Med Biol Res 40: 1003-1010, 2007.
47. Lin CC and Shieh DE: The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med 24: 31-36, 1996.
48. Kubo M, Matsuda H, Tanaka M, Kimura Y, Okuda H, Higashino M, Tani T, Namba K and Arichi S: Studies on Scutellariae radix. VII. Anti-Arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo) 32: 2724-2729, 1984.
49. Zhang XP, Tian H, Lai YH, Chen L, Zhang L, Cheng QH, Yan W, Li Y, Li QY, He Q and Wang F: Protective effects and mechanisms of Baicalin and octreotide on renal injury of rats with severe acute pancreatitis. World J Gastroenterol 13: 5079-5089, 2007.
50. Ikezoe T, Chen SS, Heber D, Taguchi H and Koeffler HP: Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49: 285-292, 2001.
51. Sun H, Che QM, Zhao X and Pu XP: Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur J Pharmacol 631: 53-60, 2010.
52. Hyun J and Jung Y: MicroRNAs in liver fibrosis: Focusing on the interaction with hedgehog signaling. World J Gastroenterol 22: 6652-6662, 2016.
53. Akhtar MM, Micolucci L, Islam MS, Olivieri F and Procopio AD: Bioinformatic tools for microRNA dissection. Nucleic Acids Res 44: 24-44, 2016.
54. Ambros V: microRNAs: Tiny regulators with great potential. Cell 107: 823-826, 2001.
55. Babin PJ and Gibbons GF: The evolution of plasma cholesterol: Direct utility or a spandrel of hepatic lipid metabolism? Prog Lipid Res 48: 73-91, 2009.
56. Soupene E and Kuypers FA: Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 233: 507-521, 2008.
57. Lopes-Marques M, Cunha I, Reis-Henriques MA, Santos MM and Castro LF: Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol Biol 13: 271, 2013.
58. Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H and Yamamoto TT: A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc Natl Acad Sci USA 94: 2880-2884, 1997.
59. Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al: ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13: 91-98, 2017.
60. Orlando UD, Garona J, Ripoll GV, Maloberti PM, Solano ÁR, Avagnina A, Gomez DE, Alonso DF and Podestá EJ: The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: A novel therapeutic target. PloS One 7: e40794, 2012.